Targeting ALK Rearrangements in NSCLC: Current State of the Art

Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the approval of the first-generation ALK inhibitor crizotinib which achieved better results in prolonging the progression-free survival (PFS) comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ling, Zhu, Liping, Sun, Yilan, Stebbing, Justin, Selvaggi, Giovanni, Zhang, Yongchang, Yu, Zhentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020874/
https://www.ncbi.nlm.nih.gov/pubmed/35463328
http://dx.doi.org/10.3389/fonc.2022.863461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020874/
https://www.ncbi.nlm.nih.gov/pubmed/35463328
http://dx.doi.org/10.3389/fonc.2022.863461

Ejemplares similares